♥

Natco Pharma Limited

ISIN : INE987B01026
NSE : NATCOPHARM
BSE : 524816
Face Value : 2
Industry : Pharmaceuticals & Drugs

EPS : 77.34
EPS (TTM) : 91.36
Price to Earning (P/E) : 10.33
Book Value : 326.99
Price to Bookvalue (P/B) : 2.44
Dividend Yield : 0 %
Return on Equity (ROE) : 25.88 %
Return on Capital Employed (ROCE) : 30.08 %

Natco Pharma share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	984.6 - 1027.85 4.4 %
Low / High	978.65 - 1033.2 5.6 %
Trade Volume	57,340
52 Week Low / High	752.1 - 1059.6 40.9 %

YOU MAY ALSO LIKE

High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Share Market basics for beginners
Share Market jargons in simple terms
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Stock market course tutorial
Stock Market Investment Course explained in simple words.

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR NATCO PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	5968	8846	4321	4925	8979	11405	10314	7586	10683	13626
Total Income	6106	9189	4526	5133	9269	11602	10608	7956	11103	14107
Total Expenditure	6154	4893	3368	3866	5588	6125	5734	4905	5710	5578
Other Income	138	343	205	208	290	197	294	370	420	481
Operating Profit	-48	4296	1158	1267	3681	5477	4874	3051	5393	8529
Interest	67	42	38	38	27	42	42	46	62	52
PBDT	-115	4254	1120	1229	3654	5435	4832	3005	5331	8477
Depreciation	381	396	417	415	410	435	436	442	555	441
Profit Before Tax	-496	3858	703	814	3244	5000	4396	2563	4776	8036
Tax	9	654	135	191	486	797	706	436	913	1351
Profit After Tax	-505	3204	568	623	2758	4203	3690	2127	3863	6685
Net Profit	-505	3204	568	623	2758	4203	3690	2127	3863	6685
Equity Capital	365	365	365	365	365	358	358	358	358	358
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	-2.77	17.56	3.11	3.41	15.11	23.48	20.61	11.88	21.58	37.35
Diluted Eps After Extraordinary Items	-2.77	17.55	3.11	3.41	15.11	23.26	20.6	11.88	21.56	37.32
Diluted Eps Before Extraordinary Items	-2.77	17.55	3.11	3.41	15.11	23.26	20.6	11.88	21.56	37.32

STANDALONE QUARTERLY RESULT FOR NATCO PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	5141	8057	3511	4130	7812	10483	9305	6253	9648	12369
Total Income	5245	8389	3673	4316	7987	10629	9552	6548	10007	12767
Total Expenditure	5518	4263	2810	3455	4535	5446	4882	3870	5121	4739
Other Income	104	332	162	186	175	146	247	295	359	398
Operating Profit	-273	4126	863	861	3452	5183	4670	2678	4886	8028
Interest	42	27	17	30	12	32	30	38	45	44
PBDT	-315	4099	846	831	3440	5151	4640	2640	4841	7984
Depreciation	356	369	383	381	376	399	400	404	516	404
Profit Before Tax	-671	3730	463	450	3064	4752	4240	2236	4325	7580
Tax	-58	650	86	77	523	699	638	316	834	1217
Profit After Tax	-613	3080	377	373	2541	4053	3602	1920	3491	6363
Net Profit	-613	3080	377	373	2541	4053	3602	1920	3491	6363
Equity Capital	365	365	365	365	365	358	358	358	358	358
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	-3.36	16.88	2.07	2.04	13.92	22.64	20.12	10.73	19.5	35.55
Diluted Eps After Extraordinary Items	-3.36	16.87	2.07	2.04	13.92	22.43	20.11	10.72	19.49	35.53
Diluted Eps Before Extraordinary Items	-3.36	16.87	2.07	2.04	13.92	22.43	20.11	10.72	19.49	35.53

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR NATCO PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	19448	27071	39988
Total Income	20438	28117	41269
Total Expenditure	16813	17715	22474
Other Income	990	1046	1281
Operating Profit	3625	10402	18795
Interest	177	145	192
PBDT	3448	10257	18603
Depreciation	1426	1638	1868
Profit Before Tax	2022	8619	16735
Tax	322	1466	2852
Profit After Tax	1700	7153	13883
Net Profit	1700	7153	13883
Equity Capital	365	365	358
Face Value (IN RS)	2	2	2
Reserves	42271	48373	58173
Calculated EPS	9.32	39.19	77.56
Diluted Eps After Extraordinary Items	9.32	39.18	77.34
Diluted Eps Before Extraordinary Items	9.32	39.18	77.34

STANDALONE ANNUAL RESULT FOR NATCO PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	17678	23510	35689
Total Income	18624	24365	36736
Total Expenditure	15548	15063	19319
Other Income	946	855	1047
Operating Profit	3076	9302	17417
Interest	133	86	145
PBDT	2943	9216	17272
Depreciation	1384	1509	1719
Profit Before Tax	1559	7707	15553
Tax	168	1336	2487
Profit After Tax	1391	6371	13066
Net Profit	1391	6371	13066
Equity Capital	365	365	358
Face Value (IN RS)	2	2	2
Reserves	41554	46655	55565
Calculated EPS	7.62	34.91	72.99
Diluted Eps After Extraordinary Items	7.63	34.9	72.79
Diluted Eps Before Extraordinary Items	7.63	34.9	72.79

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR NATCO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	2084 Cr	2216.3 Cr	2881.3 Cr	4331.8 Cr
Sales	1696.8 Cr	1947 Cr	2798.5 Cr	3957.6 Cr
Job Work/ Contract Receipts	10.1 Cr	4.6 Cr	7.6 Cr	90 Lk
Processing Charges / Service Income	15.3 Cr	224.8 Cr	65 Cr	353.3 Cr
Net Sales	2052.1 Cr	1944.8 Cr	2707.1 Cr	3998.8 Cr
Increase/Decrease in Stock	-48.1 Cr	-16.8 Cr	-23.7 Cr	42.7 Cr
Raw Material Consumed	531.8 Cr	545.2 Cr	606.9 Cr	625.2 Cr
Opening Raw Materials	160.1 Cr	337.1 Cr	243.7 Cr	222.3 Cr
Purchases Raw Materials	522.2 Cr	393.3 Cr	403.7 Cr	455.6 Cr
Closing Raw Materials	337.1 Cr	243.7 Cr	216.2 Cr	204.1 Cr
Other Direct Purchases / Brought in cost	186.6 Cr	58.5 Cr	175.7 Cr	151.4 Cr
Power & Fuel Cost	61.1 Cr	76.4 Cr	81.9 Cr	88.9 Cr
Electricity & Power	61.1 Cr	76.4 Cr	81.9 Cr	88.9 Cr
Employee Cost	414.9 Cr	444.8 Cr	486.7 Cr	525 Cr
Salaries, Wages & Bonus	353 Cr	391.3 Cr	438 Cr	473.1 Cr
Contributions to EPF & Pension Funds	23.8 Cr	25.7 Cr	26.7 Cr	29.1 Cr
Workmen and Staff Welfare Expenses	13.9 Cr	13.5 Cr	10.6 Cr	11.4 Cr
Other Manufacturing Expenses	291.9 Cr	344.9 Cr	279.6 Cr	368.4 Cr
Repairs and Maintenance	54.4 Cr	59.9 Cr	65.6 Cr	70.4 Cr
Packing Material Consumed	27.7 Cr	32.5 Cr	44.1 Cr	48.7 Cr
General and Administration Expenses	116.7 Cr	161.5 Cr	208.8 Cr	313 Cr
Rent , Rates & Taxes	37 Cr	38.9 Cr	55.7 Cr	136.2 Cr
Insurance	19.9 Cr	26.3 Cr	27.6 Cr	29.7 Cr
Professional and legal fees	29.8 Cr	49 Cr	73.5 Cr	84.7 Cr
Traveling and conveyance	16.2 Cr	22.2 Cr	37.1 Cr	49.9 Cr
Selling and Distribution Expenses	34.4 Cr	43.7 Cr	96.1 Cr	153 Cr
Advertisement & Sales Promotion	21.1 Cr	32.6 Cr	65.7 Cr	132.5 Cr
Freight and Forwarding	13.3 Cr	11.1 Cr	30.4 Cr	20.5 Cr
Miscellaneous Expenses	43.2 Cr	81.6 Cr	59.1 Cr	131.2 Cr
Bad debts /advances written off	11.7 Cr	19.9 Cr	10.8 Cr	5.1 Cr
Provision for doubtful debts	0	27.1 Cr	0	22.7 Cr
Loss on disposal of fixed assets(net)	0	0	0	1.7 Cr
Loss on sale of non-trade current investments	0	0	0	90 Lk
Total Expenditure	1445.9 Cr	1681.3 Cr	1795.4 Cr	2247.4 Cr
Other Income	103.6 Cr	99 Cr	128.5 Cr	128.1 Cr
Interest Received	56.6 Cr	39 Cr	51.2 Cr	101 Cr
Dividend Received	0	20 Lk	10 Lk	30 Lk
Profit on sale of Fixed Assets	32 Cr	42.7 Cr	17.8 Cr	0
Provision Written Back	0	1.6 Cr	23.9 Cr	0
Foreign Exchange Gains	4 Cr	10.3 Cr	21.4 Cr	10.3 Cr
Operating Profit	709.8 Cr	362.5 Cr	1040.2 Cr	1879.5 Cr
Interest	13.3 Cr	17.7 Cr	14.5 Cr	19.2 Cr
Bank Charges etc	4.5 Cr	4.5 Cr	5 Cr	7.2 Cr
PBDT	696.5 Cr	344.8 Cr	1025.7 Cr	1860.3 Cr
Depreciation	116.9 Cr	142.6 Cr	163.8 Cr	186.8 Cr
Profit Before Taxation & Exceptional Items	579.6 Cr	202.2 Cr	861.9 Cr	1673.5 Cr
Profit Before Tax	579.6 Cr	202.2 Cr	861.9 Cr	1673.5 Cr
Provision for Tax	137.2 Cr	32.2 Cr	146.6 Cr	285.2 Cr
Current Income Tax	140.8 Cr	47.8 Cr	162.5 Cr	314.8 Cr
Deferred Tax	14.4 Cr	40.4 Cr	37.5 Cr	-30.8 Cr
Profit After Tax	442.4 Cr	170 Cr	715.3 Cr	1388.3 Cr
Minority Interest	-1.5 Cr	0	0	0
Consolidated Net Profit	440.9 Cr	170 Cr	715.3 Cr	1388.3 Cr
Profit Balance B/F	2239.1 Cr	2568.2 Cr	2666.6 Cr	3292.3 Cr
Appropriations	2680 Cr	2738.2 Cr	3381.9 Cr	4680.6 Cr
Other Appropriation	15.99 Cr	-10.33 Cr	-10.8 Cr	212.9 Cr
Equity Dividend %	262.5	225	275	475
Earnings Per Share	24.16	9.32	39.19	77.56
Adjusted EPS	24.16	9.32	39.19	77.56

STANDALONE PROFIT / LOSS FOR NATCO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	1685.4 Cr	1842.6 Cr	2397.6 Cr	3757.9 Cr
Sales	1634.3 Cr	1607.1 Cr	2314.8 Cr	3383.7 Cr
Job Work/ Contract Receipts	10.1 Cr	4.6 Cr	7.6 Cr	90 Lk
Processing Charges / Service Income	15.3 Cr	224.8 Cr	65 Cr	353.3 Cr
Net Sales	1653.5 Cr	1767.8 Cr	2351 Cr	3568.9 Cr
Increase/Decrease in Stock	-46.9 Cr	-5.5 Cr	34.6 Cr	17.2 Cr
Raw Material Consumed	519.2 Cr	507.6 Cr	451 Cr	508.6 Cr
Opening Raw Materials	160.1 Cr	337.1 Cr	243.7 Cr	222.3 Cr
Purchases Raw Materials	522.2 Cr	393.3 Cr	403.7 Cr	455.6 Cr
Closing Raw Materials	337.1 Cr	243.7 Cr	216.2 Cr	204.1 Cr
Other Direct Purchases / Brought in cost	174 Cr	20.9 Cr	19.8 Cr	34.8 Cr
Power & Fuel Cost	59.4 Cr	76.4 Cr	81.9 Cr	88.9 Cr
Electricity & Power	59.4 Cr	76.4 Cr	81.9 Cr	88.9 Cr
Employee Cost	380 Cr	410.1 Cr	425.7 Cr	454.9 Cr
Salaries, Wages & Bonus	318.3 Cr	357.2 Cr	379.6 Cr	405.7 Cr
Contributions to EPF & Pension Funds	23.7 Cr	25.4 Cr	24.5 Cr	27.4 Cr
Workmen and Staff Welfare Expenses	13.8 Cr	13.2 Cr	10.2 Cr	10.4 Cr
Other Manufacturing Expenses	160.5 Cr	340.8 Cr	269.9 Cr	341.7 Cr
Repairs and Maintenance	54.5 Cr	59.9 Cr	65.5 Cr	70.3 Cr
Packing Material Consumed	27.7 Cr	32.5 Cr	44.1 Cr	48.7 Cr
General and Administration Expenses	92.6 Cr	122.5 Cr	155.7 Cr	253.1 Cr
Rent , Rates & Taxes	22 Cr	22.3 Cr	41.8 Cr	118.4 Cr
Insurance	19.7 Cr	25.9 Cr	26.1 Cr	27.6 Cr
Professional and legal fees	22.8 Cr	40.3 Cr	43.6 Cr	56.7 Cr
Traveling and conveyance	15.2 Cr	19.1 Cr	31 Cr	40.5 Cr
Selling and Distribution Expenses	29.2 Cr	27 Cr	59.5 Cr	117.4 Cr
Advertisement & Sales Promotion	16.2 Cr	18.1 Cr	34.5 Cr	100.9 Cr
Freight and Forwarding	13 Cr	8.9 Cr	25 Cr	16.5 Cr
Miscellaneous Expenses	41.9 Cr	75.9 Cr	51.9 Cr	150.1 Cr
Bad debts /advances written off	11.7 Cr	19.9 Cr	10.8 Cr	5.1 Cr
Provision for doubtful debts	0	27.1 Cr	0	22.7 Cr
Loss on disposal of fixed assets(net)	0	0	0	1.7 Cr
Loss on sale of non-trade current investments	0	0	0	90 Lk
Total Expenditure	1235.9 Cr	1554.8 Cr	1530.2 Cr	1931.9 Cr
Other Income	101.1 Cr	94.6 Cr	109.4 Cr	104.7 Cr
Interest Received	56.2 Cr	37.7 Cr	43 Cr	85.3 Cr
Dividend Received	0	20 Lk	10 Lk	30 Lk
Profit on sale of Fixed Assets	32 Cr	42.7 Cr	17.8 Cr	0
Provision Written Back	0	0	23.9 Cr	0
Foreign Exchange Gains	7.5 Cr	11.4 Cr	19.5 Cr	9.4 Cr
Operating Profit	518.7 Cr	307.6 Cr	930.2 Cr	1741.7 Cr
Interest	11.3 Cr	13.3 Cr	8.6 Cr	14.5 Cr
Bank Charges etc	2.5 Cr	3.1 Cr	1.6 Cr	3.8 Cr
PBDT	507.4 Cr	294.3 Cr	921.6 Cr	1727.2 Cr
Depreciation	115.2 Cr	138.4 Cr	150.9 Cr	171.9 Cr
Profit Before Taxation & Exceptional Items	392.2 Cr	155.9 Cr	770.7 Cr	1555.3 Cr
Profit Before Tax	392.2 Cr	155.9 Cr	770.7 Cr	1555.3 Cr
Provision for Tax	82.7 Cr	16.8 Cr	133.6 Cr	248.7 Cr
Current Income Tax	86.3 Cr	32.5 Cr	132.9 Cr	283.1 Cr
Deferred Tax	14.5 Cr	40.3 Cr	54.1 Cr	-35.6 Cr
Profit After Tax	309.5 Cr	139.1 Cr	637.1 Cr	1306.6 Cr
Consolidated Net Profit	309.5 Cr	139.1 Cr	637.1 Cr	1306.6 Cr
Profit Balance B/F	2322.5 Cr	2520.3 Cr	2587.1 Cr	3134.6 Cr
Appropriations	2632 Cr	2659.4 Cr	3224.2 Cr	4441.2 Cr
Other Appropriation	15.89 Cr	-9.33 Cr	-10.8 Cr	44 Cr
Equity Dividend %	262.5	225	275	475
Earnings Per Share	16.96	7.62	34.91	72.99
Adjusted EPS	16.96	7.62	34.91	72.99

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR NATCO PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	579.6 Cr	202.2 Cr	861.9 Cr	1673.5 Cr
Adjustment	62.1 Cr	123.9 Cr	102 Cr	133.8 Cr
Changes In working Capital	-212.9 Cr	-231.4 Cr	62.7 Cr	-309.4 Cr
Cash Flow after changes in Working Capital	428.8 Cr	94.7 Cr	1026.6 Cr	1497.9 Cr
Cash Flow from Operating Activities	298.8 Cr	46.5 Cr	849.1 Cr	1211.6 Cr
Cash Flow from Investing Activities	-103.3 Cr	-5.3 Cr	-477.1 Cr	-1032.7 Cr
Cash Flow from Financing Activitie	-185.7 Cr	34.8 Cr	-363 Cr	-246.9 Cr
Net Cash Inflow / Outflow	9.8 Cr	76 Cr	9 Cr	-68 Cr
Opening Cash & Cash Equivalents	19.8 Cr	25.8 Cr	111.1 Cr	131.9 Cr
Effect of Foreign Exchange Fluctuations	-3.8 Cr	9.3 Cr	11.8 Cr	6.5 Cr
Closing Cash & Cash Equivalent	25.8 Cr	111.1 Cr	131.9 Cr	70.4 Cr

STANDALONE CASH FLOW FOR NATCO PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	392.2 Cr	155.9 Cr	770.7 Cr	1555.3 Cr
Adjustment	58.4 Cr	118.5 Cr	85.4 Cr	150.9 Cr
Changes In working Capital	-190.2 Cr	-184.2 Cr	76.7 Cr	-257.8 Cr
Cash Flow after changes in Working Capital	260.4 Cr	90.2 Cr	932.8 Cr	1448.4 Cr
Cash Flow from Operating Activities	183.5 Cr	57.7 Cr	784.4 Cr	1196.4 Cr
Cash Flow from Investing Activities	-3.2 Cr	-92.5 Cr	-436.6 Cr	-960.5 Cr
Cash Flow from Financing Activitie	-183.1 Cr	35.6 Cr	-346.8 Cr	-237.3 Cr
Net Cash Inflow / Outflow	-2.8 Cr	80 Lk	1 Cr	-1.4 Cr
Opening Cash & Cash Equivalents	7.9 Cr	5.1 Cr	5.9 Cr	6.9 Cr
Closing Cash & Cash Equivalent	5.1 Cr	5.9 Cr	6.9 Cr	5.5 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR NATCO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	36.5 Cr	36.5 Cr	36.5 Cr	35.8 Cr
Equity - Authorised	40 Cr	40 Cr	40 Cr	40 Cr
Equity - Issued	36.5 Cr	36.5 Cr	36.5 Cr	35.8 Cr
Equity Paid Up	36.5 Cr	36.5 Cr	36.5 Cr	35.8 Cr
Face Value	2	2	2	2
Total Reserves	4067.6 Cr	4223.7 Cr	4837.3 Cr	5817.3 Cr
Securities Premium	1391.5 Cr	1407.8 Cr	1406.5 Cr	1201.9 Cr
Capital Reserves	51.6 Cr	51.6 Cr	51.6 Cr	51.6 Cr
Profit & Loss Account Balance	2568.2 Cr	2666.6 Cr	3292.3 Cr	4465.7 Cr
General Reserves	59.5 Cr	59.5 Cr	59.5 Cr	59.5 Cr
Reserve excluding Revaluation Reserve	4067.6 Cr	4223.7 Cr	4837.3 Cr	5817.3 Cr
Shareholder's Funds	4121.6 Cr	4263.6 Cr	4873.8 Cr	5853.1 Cr
Minority Interest	1.8 Cr	0	0	0
Unsecured Loans	90 Lk	0	0	0
Deferred Tax Assets / Liabilities	41.3 Cr	30.1 Cr	12.4 Cr	-19.2 Cr
Deferred Tax Assets	64.8 Cr	127.8 Cr	195.4 Cr	227.9 Cr
Deferred Tax Liability	106.1 Cr	157.9 Cr	207.8 Cr	208.7 Cr
Other Long Term Liabilities	1.1 Cr	9.3 Cr	2.8 Cr	9.3 Cr
Long Term Provisions	99.6 Cr	95.7 Cr	85.3 Cr	70.9 Cr
Total Non-Current Liabilities	142.9 Cr	135.1 Cr	100.5 Cr	61 Cr
Trade Payables	146.2 Cr	161.8 Cr	263.8 Cr	235.5 Cr
Sundry Creditors	146.2 Cr	161.8 Cr	263.8 Cr	235.5 Cr
Other Current Liabilities	98.6 Cr	126.7 Cr	227.3 Cr	238.9 Cr
Bank Overdraft / Short term credit	16.3 Cr	16.5 Cr	9.4 Cr	14.9 Cr
Advances received from customers	1.3 Cr	3 Cr	86.2 Cr	85.3 Cr
Short Term Borrowings	266.7 Cr	404 Cr	165 Cr	363.2 Cr
Secured ST Loans repayable on Demands	128.4 Cr	289 Cr	74.9 Cr	167.2 Cr
Working Capital Loans- Sec	128.4 Cr	289 Cr	74.9 Cr	167.2 Cr
Short Term Provisions	14.1 Cr	17.9 Cr	27 Cr	135.2 Cr
Provision for Tax	1.3 Cr	90 Lk	10.1 Cr	32.3 Cr
Total Current Liabilities	525.6 Cr	710.4 Cr	683.1 Cr	972.8 Cr
Total Liabilities	4791.9 Cr	5109.1 Cr	5657.4 Cr	6886.9 Cr
Gross Block	2702.1 Cr	3126.9 Cr	3375.1 Cr	3603.2 Cr
Less: Accumulated Depreciation	678.9 Cr	815.1 Cr	948.2 Cr	1112.4 Cr
Net Block	2023.2 Cr	2311.8 Cr	2426.9 Cr	2490.8 Cr
Capital Work in Progress	223.4 Cr	129.5 Cr	64.3 Cr	137.3 Cr
Non Current Investments	159.4 Cr	104.4 Cr	87.3 Cr	95.9 Cr
Long Term Investment	159.4 Cr	104.4 Cr	87.3 Cr	95.9 Cr
Quoted	70.4 Cr	40.2 Cr	0	0
Unquoted	89 Cr	64.2 Cr	87.3 Cr	95.9 Cr
Long Term Loans & Advances	44.3 Cr	61.5 Cr	78.3 Cr	112.7 Cr
Other Non Current Assets	4.3 Cr	4.7 Cr	30 Lk	26.7 Cr
Total Non-Current Assets	2454.6 Cr	2611.9 Cr	2657.1 Cr	2863.4 Cr
Currents Investments	144.3 Cr	203.7 Cr	305 Cr	443.5 Cr
Quoted	15.6 Cr	81.6 Cr	100.6 Cr	143.7 Cr
Unquoted	89 Cr	64.2 Cr	87.3 Cr	95.9 Cr
Inventories	798.2 Cr	762 Cr	742.9 Cr	700.5 Cr
Raw Materials	337.1 Cr	243.7 Cr	216.2 Cr	204.1 Cr
Work-in Progress	183.4 Cr	175 Cr	129.3 Cr	102.3 Cr
Finished Goods	130.3 Cr	206.7 Cr	278.8 Cr	238.3 Cr
Packing Materials	31 Cr	31.1 Cr	30.3 Cr	42.2 Cr
Stores and Spare	76.9 Cr	96.5 Cr	73.6 Cr	77.5 Cr
Sundry Debtors	412.9 Cr	620.6 Cr	856.1 Cr	1188.9 Cr
Debtors more than Six months	0	86.6 Cr	19.6 Cr	13.9 Cr
Debtors Others	428 Cr	576.2 Cr	851.5 Cr	1194.7 Cr
Cash and Bank	283.5 Cr	206.1 Cr	546.3 Cr	952.9 Cr
Cash in hand	50 Lk	40 Lk	30 Lk	30 Lk
Balances at Bank	283 Cr	205.7 Cr	546 Cr	952.6 Cr
Other Current Assets	94.7 Cr	88.1 Cr	64.4 Cr	99.5 Cr
Interest accrued on Investments	36.2 Cr	25.2 Cr	28.5 Cr	66.4 Cr
Prepaid Expenses	22.6 Cr	32.6 Cr	28.3 Cr	28.9 Cr
Short Term Loans and Advances	603.7 Cr	616.7 Cr	485.6 Cr	638.2 Cr
Advances recoverable in cash or in kind	112.3 Cr	100.1 Cr	66 Cr	110.5 Cr
Total Current Assets	2337.3 Cr	2497.2 Cr	3000.3 Cr	4023.5 Cr
Net Current Assets (Including Current Investments)	1811.7 Cr	1786.8 Cr	2317.2 Cr	3050.7 Cr
Total Assets	4791.9 Cr	5109.1 Cr	5657.4 Cr	6886.9 Cr
Contingent Liabilities	1.2 Cr	8 Cr	14.6 Cr	40 Lk
Total Debt	267.6 Cr	404 Cr	165 Cr	363.2 Cr
Book Value	224.88	233.44	267.06	326.99
Adjusted Book Value	224.88	233.44	267.06	326.99

STANDALONE BALANCE SHEET FOR NATCO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	36.5 Cr	36.5 Cr	36.5 Cr	35.8 Cr
Equity - Authorised	40 Cr	40 Cr	40 Cr	40 Cr
Equity - Issued	36.5 Cr	36.5 Cr	36.5 Cr	35.8 Cr
Equity Paid Up	36.5 Cr	36.5 Cr	36.5 Cr	35.8 Cr
Face Value	2	2	2	2
Total Reserves	4037 Cr	4151.9 Cr	4665.5 Cr	5556.5 Cr
Securities Premium	1391.5 Cr	1407.8 Cr	1406.5 Cr	1201.9 Cr
Capital Reserves	51.6 Cr	51.6 Cr	51.6 Cr	51.6 Cr
Profit & Loss Account Balance	2520.3 Cr	2586.8 Cr	3134.6 Cr	4226.3 Cr
General Reserves	59.5 Cr	59.5 Cr	59.5 Cr	59.5 Cr
Reserve excluding Revaluation Reserve	4037 Cr	4151.9 Cr	4665.5 Cr	5556.5 Cr
Shareholder's Funds	4091.1 Cr	4191.9 Cr	4702 Cr	5592.3 Cr
Unsecured Loans	90 Lk	0	0	0
Deferred Tax Assets / Liabilities	41.3 Cr	30 Cr	28.9 Cr	-7.1 Cr
Deferred Tax Assets	64.9 Cr	127.9 Cr	178.9 Cr	215.8 Cr
Deferred Tax Liability	106.2 Cr	157.9 Cr	207.8 Cr	208.7 Cr
Other Long Term Liabilities	1.1 Cr	9.2 Cr	2.7 Cr	5.2 Cr
Long Term Provisions	99.6 Cr	95.7 Cr	85.3 Cr	70.9 Cr
Total Non-Current Liabilities	142.9 Cr	134.9 Cr	116.9 Cr	69 Cr
Trade Payables	139.5 Cr	141.2 Cr	182.4 Cr	183.3 Cr
Sundry Creditors	139.5 Cr	141.2 Cr	182.4 Cr	183.3 Cr
Other Current Liabilities	110.7 Cr	104 Cr	201.4 Cr	204.7 Cr
Bank Overdraft / Short term credit	16.3 Cr	16.5 Cr	9.4 Cr	14.9 Cr
Advances received from customers	17.9 Cr	4.5 Cr	95 Cr	83.5 Cr
Short Term Borrowings	255.5 Cr	389 Cr	159.9 Cr	363.2 Cr
Secured ST Loans repayable on Demands	128.4 Cr	289 Cr	74.9 Cr	167.2 Cr
Working Capital Loans- Sec	128.4 Cr	289 Cr	74.9 Cr	167.2 Cr
Short Term Provisions	12.8 Cr	17 Cr	25.3 Cr	134.4 Cr
Provision for Tax	0	0	8.4 Cr	31.5 Cr
Total Current Liabilities	518.5 Cr	651.2 Cr	569 Cr	885.6 Cr
Total Liabilities	4752.5 Cr	4978 Cr	5387.9 Cr	6546.9 Cr
Gross Block	2678.3 Cr	2977.8 Cr	3157.1 Cr	3359.5 Cr
Less: Accumulated Depreciation	672.4 Cr	803.6 Cr	923.3 Cr	1072.8 Cr
Net Block	2005.9 Cr	2174.2 Cr	2233.8 Cr	2286.7 Cr
Capital Work in Progress	223.4 Cr	128.7 Cr	62.8 Cr	133.9 Cr
Non Current Investments	302.4 Cr	430.4 Cr	517.6 Cr	577.8 Cr
Long Term Investment	302.4 Cr	430.4 Cr	517.6 Cr	577.8 Cr
Quoted	70.4 Cr	40.2 Cr	0	0
Unquoted	232 Cr	390.2 Cr	517.6 Cr	598.8 Cr
Long Term Loans & Advances	55.6 Cr	61.9 Cr	78.8 Cr	111.5 Cr
Other Non Current Assets	4.2 Cr	4.6 Cr	20 Lk	26.6 Cr
Total Non-Current Assets	2591.5 Cr	2799.8 Cr	2893.2 Cr	3136.5 Cr
Currents Investments	34.6 Cr	119.6 Cr	139.9 Cr	163.9 Cr
Quoted	15.6 Cr	81.6 Cr	100.6 Cr	116.8 Cr
Unquoted	232 Cr	390.2 Cr	517.6 Cr	598.8 Cr
Inventories	769.2 Cr	697.7 Cr	616 Cr	596.9 Cr
Raw Materials	337.1 Cr	243.7 Cr	216.2 Cr	204.1 Cr
Work-in Progress	183.4 Cr	175 Cr	129.3 Cr	102.3 Cr
Finished Goods	130.3 Cr	142.4 Cr	151.9 Cr	134.7 Cr
Packing Materials	31 Cr	31.1 Cr	30.3 Cr	42.2 Cr
Stores and Spare	76.9 Cr	96.5 Cr	73.6 Cr	77.5 Cr
Sundry Debtors	399.8 Cr	575.6 Cr	793.1 Cr	1076.6 Cr
Debtors more than Six months	0	85.3 Cr	16.8 Cr	9.8 Cr
Debtors Others	414.9 Cr	532.5 Cr	791.3 Cr	1086.5 Cr
Cash and Bank	262.8 Cr	100.9 Cr	412 Cr	864.9 Cr
Cash in hand	50 Lk	40 Lk	30 Lk	30 Lk
Balances at Bank	262.3 Cr	100.5 Cr	411.7 Cr	864.6 Cr
Other Current Assets	95.2 Cr	78.1 Cr	57.6 Cr	86.1 Cr
Interest accrued on Investments	36.1 Cr	25.2 Cr	28.5 Cr	56.7 Cr
Interest accrued and or due on loans	1.1 Cr	0	0	0
Prepaid Expenses	22.1 Cr	30.9 Cr	25.1 Cr	26.3 Cr
Short Term Loans and Advances	599.4 Cr	606.3 Cr	476.1 Cr	622 Cr
Advances recoverable in cash or in kind	110 Cr	93.2 Cr	59.4 Cr	99.1 Cr
Total Current Assets	2161 Cr	2178.2 Cr	2494.7 Cr	3410.4 Cr
Net Current Assets (Including Current Investments)	1642.5 Cr	1527 Cr	1925.7 Cr	2524.8 Cr
Total Assets	4752.5 Cr	4978 Cr	5387.9 Cr	6546.9 Cr
Contingent Liabilities	1.2 Cr	8 Cr	14.6 Cr	40 Lk
Total Debt	256.4 Cr	389 Cr	159.9 Cr	363.2 Cr
Book Value	223.21	229.5	257.64	312.42
Adjusted Book Value	223.21	229.5	257.64	312.42

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR NATCO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	24.16	9.32	39.19	77.56
CEPS(Rs)	30.65	17.13	48.17	87.99
DPS(Rs)	5.25	4.5	5.5	9.5
Book NAV/Share(Rs)	224.88	233.44	267.06	326.99
Tax Rate(%)	23.67	15.92	17.01	17.04
Margin Ratios
Core EBITDA Margin(%)	29.09	11.89	31.64	40.43
EBIT Margin(%)	28.45	9.92	30.42	39.08
Pre Tax Margin(%)	27.81	9.12	29.91	38.63
PAT Margin (%)	21.23	7.67	24.83	32.05
Cash Profit Margin (%)	26.84	14.1	30.51	36.36
Performance Ratios
ROA(%)	9.43	3.43	13.29	22.13
ROE(%)	11.27	4.06	15.66	25.88
ROCE(%)	13.99	4.86	18.06	30.08
Asset Turnover(x)	0.44	0.45	0.54	0.69
Sales/Fixed Asset(x)	0.86	0.76	0.89	1.24
Working Capital/Sales(x)	1.15	1.24	1.24	1.42
Efficiency Ratios
Fixed Capital/Sales(x)	1.16	1.32	1.13	0.81
Receivable days	84.44	85.1	93.53	86.16
Inventory Days	118.77	128.47	95.32	60.81
Payable days	50.75	106.38	133.18	136.43
Valuation Parameters
PER(x)	34.16	81.3	14.38	12.27
PCE(x)	26.92	44.21	11.7	10.81
Price/Book(x)	3.67	3.24	2.11	2.91
Yield(%)	0.64	0.59	0.98	1
EV/Net Sales(x)	7.33	7.21	3.66	4.11
EV/Core EBITDA(x)	21.19	38.67	9.52	8.75
EV/EBIT(x)	25.37	63.75	11.3	9.71
EV/CE(x)	3.14	2.74	1.75	2.65
M Cap / Sales	7.34	7.11	3.8	4.26
Growth Ratio
Net Sales Growth(%)	7.16	-5.23	39.2	47.72
Core EBITDA Growth(%)	2.87	-48.93	186.95	80.69
EBIT Growth(%)	0.46	-62.91	298.55	93.14
PAT Growth(%)	-3.43	-61.57	320.77	94.09
EPS Growth(%)	-4.58	-61.44	320.76	97.88
Financial Stability Ratios
Total Debt/Equity(x)	0.07	0.09	0.03	0.06
Current Ratio(x)	4.45	3.52	4.39	4.14
Quick Ratio(x)	3.02	2.5	3.35	3.47
Interest Cover(x)	44.58	12.42	60.44	88.16
Total Debt/Mcap(x)	0.02	0.03	0.02	0.02

FINANCIAL RATIOS (STANDALONE) FOR NATCO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	16.96	7.62	34.91	72.99
CEPS(Rs)	23.27	15.21	43.18	82.6
DPS(Rs)	5.25	4.5	5.5	9.5
Book NAV/Share(Rs)	223.21	229.5	257.64	312.42
Tax Rate(%)	21.09	10.78	17.33	15.99
Margin Ratios
Core EBITDA Margin(%)	24.78	11.56	34.23	43.56
EBIT Margin(%)	23.94	9.18	32.5	41.77
Pre Tax Margin(%)	23.27	8.46	32.14	41.39
PAT Margin (%)	18.36	7.55	26.57	34.77
Cash Profit Margin (%)	25.2	15.06	32.87	39.34
Performance Ratios
ROA(%)	6.59	2.86	12.29	21.9
ROE(%)	7.82	3.37	14.33	25.38
ROCE(%)	9.46	3.79	16.51	29.02
Asset Turnover(x)	0.36	0.38	0.46	0.63
Sales/Fixed Asset(x)	0.7	0.65	0.78	1.15
Working Capital/Sales(x)	1.03	1.21	1.25	1.49
Efficiency Ratios
Fixed Capital/Sales(x)	1.43	1.53	1.28	0.87
Receivable days	101.41	96.61	104.18	90.8
Inventory Days	140.08	145.29	100	58.9
Payable days	54.27	102.03	121.62	126.93
Valuation Parameters
PER(x)	48.66	99.36	16.15	13.04
PCE(x)	35.46	49.8	13.05	11.52
Price/Book(x)	3.7	3.3	2.19	3.05
Yield(%)	0.64	0.59	0.98	1
EV/Net Sales(x)	9.1	7.98	4.27	4.63
EV/Core EBITDA(x)	29.02	45.87	10.79	9.49
EV/EBIT(x)	37.31	83.39	12.88	10.53
EV/CE(x)	3.17	2.83	1.86	2.78
M Cap / Sales	9.11	7.82	4.38	4.77
Growth Ratio
Net Sales Growth(%)	-7.64	6.91	32.99	51.8
Core EBITDA Growth(%)	-26.09	-40.7	202.41	87.24
EBIT Growth(%)	-33.16	-58.07	360.58	101.44
PAT Growth(%)	-34.77	-55.06	358.02	105.09
EPS Growth(%)	-34.95	-55.06	358.02	109.1
Financial Stability Ratios
Total Debt/Equity(x)	0.06	0.09	0.03	0.06
Current Ratio(x)	4.17	3.34	4.38	3.85
Quick Ratio(x)	2.77	2.33	3.36	3.23
Interest Cover(x)	35.71	12.72	90.62	108.26
Total Debt/Mcap(x)	0.02	0.03	0.02	0.02

SHARE HOLDING PATTERN FOR NATCO PHARMA LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	48.80	48.80	48.82	48.84	49.76	49.71	49.71	49.71	49.71	49.62
FII %	11.65	11.67	11.72	11.91	11.03	12.82	13.72	16.14	17.45	17.51
DII %	1.06	0.60	0.54	0.46	0.12	0.02	0.02	0.03	0.10	0.15
Public %	24.25	25.23	24.53	23.87	24.07	23.46	25.32	24.46	24.97	26.12

PEER COMPARISON FOR NATCO PHARMA LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR NATCO PHARMA

Exchange Date	Purpose	Book Closure Dates
BSE 28-Oct-2024	Board Meeting - Quarterly Results & Interim Dividend	12-Nov-2024
BSE 23-Aug-2024	Dividend - Rs.3.0000 per share(150%)Interim Dividend
BSE 12-Aug-2024	Book Closure - A.G.M.	26-Sep-2024 30-Sep-2024
BSE 12-Aug-2024	AGM - A.G.M.	30-Sep-2024 30-Sep-2024
BSE 26-Jul-2024	Board Meeting - Quarterly Results & Interim Dividend	12-Aug-2024
BSE 09-May-2024	Board Meeting - Audited Results	27-May-2024
BSE 26-Feb-2024	Dividend - Rs.1.2500 per share(62.5%)Interim Dividend
BSE 02-Feb-2024	Board Meeting - Interim Dividend & Quarterly Results	14-Feb-2024
BSE 24-Nov-2023	Dividend - Rs.1.2500 per share(62.5%)Interim Dividend
BSE 03-Nov-2023	Board Meeting - Quarterly Results & Interim Dividend	14-Nov-2023
BSE 05-Sep-2023	Book Closure - A.G.M.	26-Sep-2023 29-Sep-2023
BSE 05-Sep-2023	AGM - A.G.M.	29-Sep-2023 29-Sep-2023
BSE 22-Aug-2023	Dividend - Rs.7.0000 per share(350%)Interim Dividend
BSE 31-Jul-2023	Board Meeting - Quarterly Results & Interim Dividend	09-Aug-2023
BSE 19-May-2023	Board Meeting - Audited Results	29-May-2023
BSE 02-Mar-2023	Board Meeting - Buy Back of Shares	08-Mar-2023
BSE 21-Feb-2023	Dividend - Rs.1.2500 per share (62.5%) Third Interim Dividend
BSE 31-Jan-2023	Board Meeting - Quarterly Results & Interim Dividend	09-Feb-2023
BSE 10-Nov-2022	Dividend - Re.0.75000 per share (37.50%) Second Interim Dividend
BSE 31-Oct-2022	Board Meeting - Quarterly Results & Second Interim Dividend	10-Nov-2022
BSE 02-Sep-2022	Book Closure - A.G.M.	27-Sep-2022 30-Sep-2022
BSE 02-Sep-2022	AGM - A.G.M.	30-Sep-2022 30-Sep-2022
BSE 18-Aug-2022	Dividend - Rs.3.5000 per share(175%)Interim Dividend
BSE 01-Aug-2022	Board Meeting - Interim Dividend & Quarterly Results	09-Aug-2022
BSE 20-May-2022	Board Meeting - Audited Results	30-May-2022
BSE 24-Feb-2022	Dividend - Rs.2.0000 per share (100%) Third Interim Dividend
BSE 07-Feb-2022	Board Meeting - Third Interim Dividend & Quarterly Results	14-Feb-2022
BSE 23-Nov-2021	Dividend - Re.0.5000 per share (25%) Second Interim Dividend
BSE 03-Nov-2021	Board Meeting - Quarterly Results & Interim Dividend	11-Nov-2021
BSE 02-Sep-2021	Book Closure - A.G.M.	27-Sep-2021 30-Sep-2021

CORPORATE ANNOUNCEMENTS FOR NATCO PHARMA

Exchange Date	Category File	Description
BSE 30-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Q2FY25 Unaudited Financial Results Earnings Call
BSE 28-Oct-2024	Intimation FILE	Board Meeting Intimation for Considering The Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2024 And 2Nd Interim Dividend If Any NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve the Unaudited financial results for the quarter and half year ended 30th September 2024 and 2nd Interim Dividend if any
BSE 11-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Mr. Vamsi Krishna Mutyala designated as Associate Vice President - CSR of the Company w.e.f. 11th October 2024
BSE 07-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarte ended 30th September 2024
BSE 07-Oct-2024	General Announcements FILE	Update Update
BSE 01-Oct-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 41st Annual General Meeting E-voting Scrutinizer Report and E-voting Results
BSE 30-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Proceedings of 41st Annual General Meeting of the company
BSE 26-Sep-2024	Intimation FILE	Closure of Trading Window Closure of Trading Window from 1st October 2024 till 48 hours from the declaration of Un-audited Financial Results for the quarter ending 30th September 2024
BSE 24-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Resignation of Mr. Sourav Chakraborty AVP- Sales and Marketing Crop Health Sciences Division w.e.f. 24/09/2024
BSE 19-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Issue of Duplicate Share Certificate
BSE 16-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Analyst / Investor meet on 20/09/2024
BSE 16-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Analyst / Investor Meet on 19th September 2024
BSE 06-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Investor Meet on 11th September 2024
BSE 06-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Notice for 41st Annual General Meeting of the company
BSE 05-Sep-2024	Intimation FILE	Book Closure Intimation Book Closure Notice for the 41st Annual General Meeting for the year 2023-24
BSE 04-Sep-2024	Intimation FILE	41St Annual General Meeting 41st Annual General Meeting Notice
BSE 04-Sep-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) Business Responsibility and Sustainability Report for the year ended 31st March 2024
BSE 04-Sep-2024	General Announcements FILE	Reg. 34 (1) Annual Report. 41st Annual Report for the year 2023-24
BSE 04-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release regarding investment of USD 8 million in eGenesis Inc. by NATCO Pharma (Canada) Inc. Subsidiary Company of NATCO Pharma Limited
BSE 02-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation investor Meeting
BSE 30-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate LOSS OF SHARE CERTIFICATE
BSE 29-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release submission of NEW ABBREVATED NEW DRUG APPLICATION (ANDA)
BSE 28-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Investor / Analyst Meeting to be held on 2nd September 2024
BSE 21-Aug-2024	General FILE	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Kantamani Ratna Kumar Vidyabhari Tummala Anila Tummala
BSE 21-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Earnings Call Transcript
BSE 16-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Issue of Duplicate Share Certificate
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Earnings Call Audio Recording weblink
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication copies
BSE 12-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Investor Presentation Investor Presentation for the quarter ended 30th June 2024
BSE 12-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Appointment of Independent Directors and Statutory Auditor

INSIDER TRADING FOR NATCO PHARMA

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 11-Sep-2024 11-Sep-2024	Sell Market	1,500 @ 0.00 (0.00 %)	AMIT SOGANI
BSE 03-Sep-2024 04-Sep-2024	Sell Market	2,000 @ 0.00 (0.00 %)	G VENKATA RAMANA
BSE 29-Aug-2024 30-Aug-2024	Sell Market	20,000 @ 0.00 (0.01 %)	SUBBA RAO MENTE
BSE 22-Aug-2024 22-Aug-2024	Sell Market	600 @ 0.00 (0.00 %)	DHRUVA KUMAR NANNAPANENI
BSE 21-Aug-2024 21-Aug-2024	Sell Market	10,000 @ 0.00 (0.00 %)	N SRILAKSHMI
BSE 19-Aug-2024 19-Aug-2024	Sell Market	11,563 @ 0.00 (0.01 %)	Kantamani Ratna Kumar
BSE 19-Aug-2024 19-Aug-2024	Sell Market	38,437 @ 0.00 (0.02 %)	Kantamani Ratna Kumar
BSE 19-Aug-2024 20-Aug-2024	Sell Market	75,000 @ 0.00 (0.04 %)	Vidyadhari Tummala
BSE 20-Aug-2024 20-Aug-2024	Sell Market	35,000 @ 0.00 (0.01 %)	Anila Tummala
BSE 28-Jun-2024 28-Jun-2024	Sell Market	500 @ 0.00 (0.00 %)	MUDDASANI PULLA REDDY
BSE 03-Jun-2024 03-Jun-2024	Sell Market	1,375 @ 0.00 (0.00 %)	PRATIMA JAIN
BSE 08-Dec-2023 11-Dec-2023	Sell Market	4,120 @ 0.00 (0.00 %)	PATIL CHANDRASEKHARA REDDY
BSE 04-Dec-2023 04-Dec-2023	Sell Market	10,000 @ 0.00 (0.00 %)	SIVARAMAKRISHNA PRASAD POTLURI
BSE 29-Nov-2023 29-Nov-2023	Sell Market	1,687 @ 0.00 (0.00 %)	JAYA POTLURI
BSE 28-Nov-2023 28-Nov-2023	Sell Market	300 @ 0.00 (0.00 %)	NDL INFRATECH PVT LTD
BSE 28-Sep-2023 29-Sep-2023	Sell Market	900 @ 0.00 (0.00 %)	M VANAJA
BSE 04-Sep-2023 04-Sep-2023	Sell Market	30,000 @ 0.00 (0.02 %)	ANILA T
BSE 04-Sep-2023 05-Sep-2023	Sell Market	60,000 @ 0.00 (0.03 %)	ANANDA BABU T
BSE 05-Sep-2023 05-Sep-2023	Sell Market	25,000 @ 0.00 (0.01 %)	PURANDHAR T
BSE 26-Jun-2023 27-Jun-2023	Buy Inter-Se Transfer	5,440,040 @ 0.00 (3.04 %)	V C NANNAPANENI
BSE 26-Jun-2023 27-Jun-2023	Sell Inter-Se Transfer	5,440,040 @ 0.00 (0.00 %)	Venkaiah Chowdary Nannapaneni HUF
BSE 17-Feb-2023 20-Feb-2023	Buy Market	10 @ 0.00 (0.00 %)	NITEESHRAO MADHAVARAM
BSE 01-Dec-2022 01-Dec-2022	Buy Market	17,400 @ 0.00 (0.01 %)	NATSOFT INFORMATION SYSTEMS PVT LTD
BSE 30-Nov-2022 30-Nov-2022	Buy Market	8,880 @ 0.00 (0.01 %)	V C NANNAPANENI
BSE 27-May-2022 27-May-2022	Buy ESOP	16,000 @ 0.00 (0.00 %)	PAVAN G BHAT
BSE 27-May-2022 27-May-2022	Buy ESOP	3,000 @ 0.00 (0.00 %)	SUBBA RAO MENTE
BSE 27-May-2022 27-May-2022	Buy ESOP	1,200 @ 0.00 (0.00 %)	VENKAT RAMESH CHEKURI
BSE 09-Dec-2021 09-Dec-2021	Buy Market	300 @ 0.00 (0.00 %)	NDL INFRA TECH PVT LTD
BSE 25-Mar-2022 25-Mar-2022	Sell Gift	18,300 @ 0.00 (0.00 %)	BAPANNA ALAPATI
BSE 03-Mar-2022 03-Mar-2022	Sell Market	350 @ 0.00 (0.00 %)	BIKKUMALLA SRINIVASA RAO

BULK BLOCK DEALS FOR NATCO PHARMA LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 21-Feb-2024	Sell BLOCK	198,742 @ 1039.15	JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED
BSE 21-Feb-2024	Buy BLOCK	198,742 @ 1039.15	THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT
BSE 25-Jan-2024	Sell BLOCK	149,926 @ 859.20	BNP PARIBAS ARBITRAGE
BSE 25-Jan-2024	Sell BLOCK	662,733 @ 859.20	BNP PARIBAS ARBITRAGE
BSE 25-Jan-2024	Buy BLOCK	149,926 @ 859.20	MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUND
BSE 25-Jan-2024	Buy BLOCK	662,733 @ 859.20	SOCIETE GENERALE
BSE 25-Oct-2022	Sell BLOCK	193,938 @ 593.90	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 25-Oct-2022	Buy BLOCK	193,938 @ 593.90	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 25-Oct-2022	Sell BLOCK	22,874 @ 593.90	ISHARES INDIA SC MAURITIUS COMPANY
BSE 25-Oct-2022	Buy BLOCK	22,874 @ 593.90	ISHARES MSCI INDIA SMALL-CAP ETF
BSE 17-Oct-2022	Sell BLOCK	193,749 @ 598.00	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 17-Oct-2022	Buy BLOCK	193,749 @ 598.00	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 17-Oct-2022	Sell BLOCK	22,852 @ 598.00	ISHARES INDIA SC MAURITIUS COMPANY
BSE 17-Oct-2022	Buy BLOCK	22,852 @ 598.00	ISHARES MSCI INDIA SMALL-CAP ETF
BSE 11-Oct-2022	Sell BLOCK	188,603 @ 616.70	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 11-Oct-2022	Buy BLOCK	188,603 @ 616.70	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 11-Oct-2022	Sell BLOCK	22,244 @ 616.70	ISHARES INDIA SC MAURITIUS COMPANY
BSE 11-Oct-2022	Buy BLOCK	22,244 @ 616.70	ISHARES MSCI INDIA SMALL-CAP ETF
BSE 19-Sep-2022	Sell BLOCK	163,024 @ 613.00	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 19-Sep-2022	Buy BLOCK	163,024 @ 613.00	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 19-Sep-2022	Sell BLOCK	19,060 @ 613.00	ISHARES INDIA SC MAURITIUS COMPANY
BSE 19-Sep-2022	Buy BLOCK	19,060 @ 613.00	ISHARES MSCI INDIA SMALL-CAP ETF
BSE 04-May-2022	Buy BLOCK	193,440 @ 786.75	ISHARES CORE MSCI TOTAL INTERNATIONAL STOCK ETF
BSE 04-May-2022	Sell BLOCK	193,440 @ 786.75	ISHARES CORE TOTAL INTERNATIONAL STOCK MAURITIUS CO

DIVIDEND BY NATCO PHARMA LIMITED

Ex Dividend Date	Dividend Type	Dividend
18-Feb-2025	INTERIM DIVIDEND	1.5
27-Nov-2024	INTERIM DIVIDEND	1.5
23-Aug-2024	INTERIM DIVIDEND	3
26-Feb-2024	INTERIM DIVIDEND	1.25
24-Nov-2023	INTERIM DIVIDEND	1.25
22-Aug-2023	INTERIM DIVIDEND	7
21-Feb-2023	INTERIM DIVIDEND	1.25
21-Nov-2022	INTERIM DIVIDEND	0.75
19-Aug-2022	INTERIM DIVIDEND	3.5
24-Feb-2022	INTERIM DIVIDEND	2
23-Nov-2021	INTERIM DIVIDEND	0.5
24-Aug-2021	INTERIM DIVIDEND	2
22-Feb-2021	INTERIM DIVIDEND	1
24-Nov-2020	INTERIM DIVIDEND	3